"Roche May Be Right" In Not Taking To Generic Drugs - IMS Health; "Innovation Surge" From 2016 Will Help Big Pharma
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Global pharmaceutical companies - traditionally originators of blockbuster drugs - may not be expected to become part of a "long list of generic players" even by 2020, according to leading industry data and consulting firm IMS Health. However, experts believe MNCs will pursue specific areas where their skill sets can offer competitive advantages
You may also be interested in...
Will Innovation Replace Branded Generics As Dominant Strategy For Big Pharma In Emerging Markets? (Part 1 of 2)
Although Deutsche Bank agrees with most analysts that emerging markets are an important growth driver for big pharma, the brokerage believes that many observers under appreciate the challenges ahead, and that familiar strategies such as branded generics and local acquisitions may be short-term plays that won't necessarily translate to long-term success in rapidly changing markets like Brazil, Russia, India and China
Will Innovation Replace Branded Generics As Dominant Strategy For Big Pharma In Emerging Markets? (Part 1 of 2)
Although Deutsche Bank agrees with most analysts that emerging markets are an important growth driver for big pharma, the brokerage believes that many observers under appreciate the challenges ahead, and that familiar strategies such as branded generics and local acquisitions may be short-term plays that won't necessarily translate to long-term success in rapidly changing markets like Brazil, Russia, India and China
Will Innovation Replace Branded Generics As Dominant Strategy For Big Pharma In Emerging Markets?
Pricing pressure will increase over time in emerging markets, hitting the bottom line of multinationals, particularly those with high exposure to branded generics, Deutsche Bank predicts.